» Articles » PMID: 38440177

Comparative Effects of Incretin-based Therapy on Doxorubicin-induced Nephrotoxicity in Rats: the Role of SIRT1/Nrf2/NF-κB/TNF-α Signaling Pathways

Overview
Journal Front Pharmacol
Date 2024 Mar 5
PMID 38440177
Authors
Affiliations
Soon will be listed here.
Abstract

Nephrotoxicity represents a major complication of using doxorubicin (DOX) in the management of several types of cancers. Increased oxidative stress and the activation of inflammatory mediators play outstanding roles in the development of DOX-induced kidney damage. This study aimed to investigate whether the two pathways of incretin-based therapy, glucagon-like peptide-1 receptor agonist (presented as semaglutide, SEM) and dipeptidyl peptidase-4 inhibitor (presented as alogliptin, ALO), differentially protect against DOX-induced nephrotoxicity in rats and to clarify the underlying molecular mechanisms. Adult male rats were divided into six groups: control (received the vehicle), DOX (20 mg/kg, single I.P. on day 8), DOX + ALO (20 mg/kg/day, P.O. for 10 days), DOX + SEM (12 μg/kg/day, S.C. for 10 days), ALO-alone, and SEM-alone groups. At the end of the study, the animals were sacrificed and their kidney functions, oxidative stress, and inflammatory markers were assessed. Kidney sections were also subjected to histopathological examinations. The co-treatment with either ALO or SEM manifested an improvement in the kidney functions, as evidenced by lower serum concentrations of creatinine, urea, and cystatin C compared to the DOX group. Lower levels of MDA, higher levels of GSH, and increased SOD activity were observed in either ALO- or SEM-treated groups than those observed in the DOX group. DOX administration resulted in decreased renal expressions of sirtuin 1 (SIRT1) and Nrf2 with increased NF-κB and TNF-α expressions, and these effects were ameliorated by treatment with either ALO or SEM. Co-treatment with either ALO or SEM showed a renoprotective effect that was mediated by their antioxidant and anti-inflammatory effects via the SIRT1/Nrf2/NF-κB/TNF-α pathway. The fact that both pathways of the incretin-based therapy demonstrate an equally positive effect in alleviating DOX-induced renal damage is equally noteworthy.

Citing Articles

Ameliorates Doxorubicin-Induced Nephrotoxicity and Potentiates Its Therapeutic Efficacy Targeting SIRT1/Nrf2, Oxidative Stress, Inflammation, and Apoptosis.

Mohmmed Hegab A, Hassanin S, Mekky R, Abuzahrah S, Hamza A, Talaat I Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006061 PMC: 11859695. DOI: 10.3390/ph18020248.


Diosmin and Coenzyme q10: Synergistic histopathological and functional protection against doxorubicin-induced hepatorenal injury in rats.

Mansour D, Hashad I, Rady M, Abd-El Razik A, Saleh D Toxicol Rep. 2024; 13:101848.

PMID: 39703765 PMC: 11655815. DOI: 10.1016/j.toxrep.2024.101848.


Potential Effect of Etoricoxib in Reducing Inflammation in Methotrexate-Induced Pulmonary Injury in Rats: Role of Oxidative Stress and the TLR4/p38-MAPK/NF-κB Signaling Pathway.

Abdelall A, Khames A, Bekhit A, Fathy M Inflammation. 2024; .

PMID: 39602008 DOI: 10.1007/s10753-024-02198-w.


Downregulation of RIP3 ameliorates the left ventricular mechanics and function after myocardial infarction modulating NF-κB/NLRP3 pathway.

Zhang H, Yin Y, Chen S, Qian P, Zou G, Liu Y Open Life Sci. 2024; 19(1):20220890.

PMID: 38911926 PMC: 11193396. DOI: 10.1515/biol-2022-0890.

References
1.
Jablonski P, Howden B, Rae D, Birrell C, Marshall V, Tange J . An experimental model for assessment of renal recovery from warm ischemia. Transplantation. 1983; 35(3):198-204. DOI: 10.1097/00007890-198303000-00002. View

2.
Carron P, Padilla M, Maurizi Balzan J . Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment. Hemodial Int. 2014; 18(4):846-7. DOI: 10.1111/hdi.12196. View

3.
Huang K, Huang J, Xie X, Wang S, Chen C, Shen X . Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells. Free Radic Biol Med. 2013; 65:528-540. DOI: 10.1016/j.freeradbiomed.2013.07.029. View

4.
Dieter B, Alicic R, Tuttle K . GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Renal Physiol. 2018; 315(6):F1519-F1525. PMC: 6337002. DOI: 10.1152/ajprenal.00211.2018. View

5.
Pan X, Yang L, Wang S, Liu Y, Yue L, Chen S . Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression. Mol Cell Biochem. 2023; 479(5):1133-1147. DOI: 10.1007/s11010-023-04784-2. View